Tag Archives: Bayer
The issue of Clinical Trials in India has once again come to the fore with the government’s efforts to woo the mighty pharma industry. The Drug Controller General of India, Mr G N Singh, has been quoted as saying that India will soon roll out a new policy to facilitate clinical trials. It is hence important to understand what are we talking about and why we need to get it right.
London: The sprouting “free health check-up camps” in India are just a tactic of pharmaceutical companies to push their products and are in violation of the Medical Council of India (MCI) guidelines, says a special investigative report in the British Medical Journal.
Washington: The US Food and Drug Administration has approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension.
Sydney: A special iPhone case and app can be used to quickly and cheaply detect heart rhythm problems and prevent strokes, according to University of Sydney research.
Chennai: The cancellation of a compulsory licence to Hyderabad-based Natco Pharma Ltd to make and sell the generic equivalent of cancer drug Nexavar will not impact public interest as there is another company selling it at a lower price, the Bayer Corporation said here on Monday.
Washington: Even as President Barack Obama is plugging his signature law to lower health care costs at home, his administration is pressurising India and other countries to impose higher prices even for lifesaver cancer drugs.
New Delhi: Pharmaceutical companies and research institutions in association with the Bill and Melinda Gates Foundation have stepped up efforts to aid research on a new drug for tuberculosis (TB), a disease that annually kills about three lakh people in India.
New Delhi: A report by the parliamentary standing committee for health and family welfare, which looked at the functioning of the Central Drugs Standard Control Organization (CDSCO), reveals that some drug companies have been writing scientific recommendations of their own products and submitting them to the Drug Controller General of India (DCGI) after getting them endorsed by top doctors for a quicker marketing approval.
Mumbai: The Controller General of Patents, Designs and Trade Marks has allowed Hyderabad-based Natco Pharma to manufacture and market the generic version of a patented cancer drug, Nexavar, in India for Rs 8,880 per month, just 3 per cent of the price charged by Germany’s Bayer AG. In return, Natco will have to pay Bayer royalty pegged at six per cent of the net sales, every quarter.